Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Denosumab.

Literature DB >> 20065634

Denosumab.

Abstract

Denosumab is an anti-receptor activator of nuclear factor (NF)-kappaB (RANK) ligand human monoclonal antibody studied as a treatment for postmenopausal osteoporosis (PMO) and bone destruction due to rheumatoid arthritis (RA) or metastatic cancers. As of February 2009, the candidate was undergoing US Food and Drug Administration review, and might be approved by October 2009. Late phase clinical trials demonstrated that denosumab possesses a similar safety profile to bisphosphonates and that it can be either equally or more effective than bisphosphonates at preventing bone loss due to PMO, RA or cancer treatment and metastases.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2009 PMID： 20065634 PMCID： PMC2726593 DOI： 10.4161/mabs.1.3.8592

Source DB: PubMed Journal: MAbs ISSN： 1942-0862 Impact factor: 5.857

18 in total

1. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. 2004.

Authors: Pirow J Bekker; Donna L Holloway; Amy S Rasmussen; Robyn Murphy; Steven W Martin; Philip T Leese; Gregory B Holmes; Colin R Dunstan; Alex M DePaoli
Journal: J Bone Miner Res Date: 2005-12 Impact factor: 6.741

2. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status.

Authors: Luis Costa; Laurence M Demers; A Gouveia-Oliveira; J Schaller; Eduardo B Costa; Miguel C de Moura; Allan Lipton
Journal: J Clin Oncol Date: 2002-02-01 Impact factor: 44.544

3. Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures.

Authors: K Matsuzaki; N Udagawa; N Takahashi; K Yamaguchi; H Yasuda; N Shima; T Morinaga; Y Toyama; Y Yabe; K Higashio; T Suda
Journal: Biochem Biophys Res Commun Date: 1998-05-08 Impact factor: 3.575

4. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.

Authors: Janet E Brown; Richard J Cook; Pierre Major; Allan Lipton; Fred Saad; Matthew Smith; Ker-Ai Lee; Ming Zheng; Yong-Jiang Hei; Robert E Coleman
Journal: J Natl Cancer Inst Date: 2005-01-05 Impact factor: 13.506

5. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL.

Authors: H Yasuda; N Shima; N Nakagawa; K Yamaguchi; M Kinosaki; S Mochizuki; A Tomoyasu; K Yano; M Goto; A Murakami; E Tsuda; T Morinaga; K Higashio; N Udagawa; N Takahashi; T Suda
Journal: Proc Natl Acad Sci U S A Date: 1998-03-31 Impact factor: 11.205

6. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group.

Authors: G N Hortobagyi; R L Theriault; A Lipton; L Porter; D Blayney; C Sinoff; H Wheeler; J F Simeone; J J Seaman; R D Knight; M Heffernan; K Mellars; D J Reitsma
Journal: J Clin Oncol Date: 1998-06 Impact factor: 44.544

7. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis.

Authors: N Nakagawa; M Kinosaki; K Yamaguchi; N Shima; H Yasuda; K Yano; T Morinaga; K Higashio
Journal: Biochem Biophys Res Commun Date: 1998-12-18 Impact factor: 3.575

8. Comparison of effects of the bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing.

Authors: Louis C Gerstenfeld; Daniel J Sacks; Megan Pelis; Zachary D Mason; Dana T Graves; Mauricio Barrero; Michael S Ominsky; Paul J Kostenuik; Elise F Morgan; Thomas A Einhorn
Journal: J Bone Miner Res Date: 2009-02 Impact factor: 6.741

9. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration.

Authors: A Wardley; N Davidson; P Barrett-Lee; A Hong; J Mansi; D Dodwell; R Murphy; T Mason; D Cameron
Journal: Br J Cancer Date: 2005-05-23 Impact factor: 7.640

10. Bone resorption predicts for skeletal complications in metastatic bone disease.

Authors: J E Brown; C S Thomson; S P Ellis; S A Gutcher; O P Purohit; R E Coleman
Journal: Br J Cancer Date: 2003-12-01 Impact factor: 7.640

14 in total

Review 1. Development trends for human monoclonal antibody therapeutics.

Authors: Aaron L Nelson; Eugen Dhimolea; Janice M Reichert
Journal: Nat Rev Drug Discov Date: 2010-09-03 Impact factor: 84.694

Review 2. [New biologics and orally available compounds. What is still in the pipeline?].

Authors: M Grünke; H Bastian; H Schulze-Koops; G-R Burmester
Journal: Z Rheumatol Date: 2010-09 Impact factor: 1.372

Review 3. Osteoclastogenesis and arthritis.

Authors: Nicola Maruotti; Maria Grano; Silvia Colucci; Francesca d'Onofrio; Francesco Paolo Cantatore
Journal: Clin Exp Med Date: 2010-11-11 Impact factor: 3.984

Denosumab.

1. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. 2004.

2. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status.

3. Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures.

4. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.

5. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL.

6. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group.

7. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis.

8. Comparison of effects of the bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing.

9. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration.

10. Bone resorption predicts for skeletal complications in metastatic bone disease.

Review 1. Development trends for human monoclonal antibody therapeutics.

Review 2. [New biologics and orally available compounds. What is still in the pipeline?].

Review 3. Osteoclastogenesis and arthritis.

Review 4. Developments in therapy with monoclonal antibodies and related proteins.

Review 5. Management of osteoporosis among the elderly with other chronic medical conditions.

6. Neoadjuvant denosumab for the treatment of a sacral osteoblastoma.

Review 7. Why TNF-α inhibition is not sufficient to avoid juxta-articular erosions in chronic arthritis?

Review 8. Interventions for managing medication-related osteonecrosis of the jaw.

Review 9. Targeting signaling pathways in prostate cancer: mechanisms and clinical trials.

Review 10. Interventions for managing medication-related osteonecrosis of the jaw.